Industries - Diabetic Retinopathy Market Analysis by Type (Non-Proliferative, Proliferative), by Management (Intraocular Steroid Injection, Anti VEGF, Vitrectomy, Laser Surgery), and by Region – Forecast to 2026

Ablation Technology Market Analysis

Diabetic Retinopathy Market Analysis by Type (Non-Proliferative, Proliferative), by Management (Intraocular Steroid Injection, Anti VEGF, Vitrectomy, Laser Surgery), and by Region – Forecast to 2026
May 2021

SKU: N/A Category:
Clear
  • Description
  • Additional information
  • Enquire about

Description

Diabetic Retinopathy Market Analysis by Type (Non-Proliferative, Proliferative), by Management (Intraocular Steroid Injection, Anti VEGF, Vitrectomy, Laser Surgery), and by Region - Forecast to 2026

Published: May 2021 | Historical Data: 2018-2020 | Base Year: 2020
SKU: ICI-HC-1119 | Number of Pages: 134 | Category: Pharmaceuticals

The global diabetic retinopathy market size was valued at USD 10.1 billion in 2020 and is expected to witness a CAGR of 5.8% during the forecast period. Rising incidences of diabetes coupled with growing vision concerns due to prolonged diabetes is a key driver for the growth of the global diabetic retinopathy market. Additionally, the increase in prevalence of chronic disorders among geriatric population, increasing medical expenditure, growing demand for minimal invasive surgeries, and growing government initiatives are some of the other drivers propelling the market growth. However, adverse effects of treatment and inadequate diagnosis are expected to restrain the global market growth.

Diabetic Retinopathy Market Analysis

By Type

Based on type, the market is segmented into non-proliferative and proliferative. In 2020, the non-proliferative segment accounted for the maximum revenue share. This segment is expected to grow at a lucrative CAGR due to increasing diabetes patients and inadequate compliances for screening retinal disorders in diabetic patients. Proliferative segment projected to grow at the highest CAGR during the forecast period. This is attributed to the increase in number of patients, and high number of aging population suffering with proliferative retinopathy.

By Management

Based on management, the market is categorized into intraocular steroid injection, anti VEGF, vitrectomy, and laser surgery. In 2020, the anti-VEGF segment accounted for largest revenue share due to broad application of drugs for early diagnosis and treatment of minor non-proliferative DR cases coupled with improved treatment and rapid recovery. The laser surgery segment is anticipated to grow at the highest CAGR during the forecast period due to its improved treatment outcomes and technological advancements.

Regional Insights

In 2020, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the well-established medical infrastructure, presence of large hospitals with advanced technologies, and high awareness in this region. Asia Pacific market is projected to exhibit a significant CAGR over the forecast period owing to the rising incidences of geriatric population, escalating demand for advanced medication and treatment, and growing focus of government for developing medical services & infrastructure in this region.

North America Diabetic Retinopathy Market Size (2018-2026), USD Billion

North America Diabetic Retinopathy Market

Competitor Insights

Some of the key players in the diabetic retinopathy market are Kowa Group (Japan); BCN Peptides (Spain); Ampio Pharmaceuticals, Inc. (U.S.); Alimera Sciences, Inc. (U.S.); Glycadia Inc. (U.S.); F. Hoffmann-La Roche AG (Switzerland); Oxurion (Belgium); AbbVie Inc. (U.S.); Regeneron Pharmaceuticals, Inc. (U.S.); Bayer AG (Germany); and Novartis International AG (Switzerland). The leading players operating in the diabetic Retinopathy industry are adopting various strategies including adoption of advanced techniques, investments in R&D, mergers & acquisitions, and regional expansions to capture a maximum revenue share.

 

This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2018 to 2026. The diabetic retinopathy market report is categorized into the following segments and subsegments:

Diabetic Retinopathy Market, By Type (Revenue, USD Billion, 2018 – 2026)

  • Non-Proliferative
  • Proliferative

Diabetic Retinopathy Market, By Management (Revenue, USD Billion, 2018 – 2026)

  • Intraocular Steroid Injection
  • Anti VEGF
  • Vitrectomy
  • Laser Surgery

Diabetic Retinopathy Market, By Region (Revenue, USD Billion, 2018 – 2026)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of LATAM
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Scope of Diabetic Retinopathy Market Report:

Key Parameters Details
Data Availability 2018-2026
Historical Years 2018-2020
Base Year Considered 2020
Forecast Period 2020-2026
Company Profiles 11
Companies Considered >40
Value Units Value in USD and CAGR in %
Market Segments Type and Management
Regional Coverage North America (U.S. and Canada), Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, Rest of LATAM), and the Middle East & Africa (South Africa, Saudi Arabia, Rest of MEA)
Key Market Players Kowa Group (Japan); BCN Peptides (Spain); Ampio Pharmaceuticals, Inc. (U.S.); Alimera Sciences, Inc. (U.S.); Glycadia Inc. (U.S.); F. Hoffmann-La Roche AG (Switzerland); Oxurion (Belgium); AbbVie Inc. (U.S.); Regeneron Pharmaceuticals, Inc. (U.S.); Bayer AG (Germany); and Novartis International AG (Switzerland)
Custom Analysis Customization up to 60 analyst hours

Diabetic Retinopathy Market, By Type (Revenue, USD Billion, 2018 – 2026)

  • Non-Proliferative
  • Proliferative

Diabetic Retinopathy Market, By Management (Revenue, USD Billion, 2018 – 2026)

  • Intraocular Steroid Injection
  • Anti VEGF
  • Vitrectomy
  • Laser Surgery

Diabetic Retinopathy Market, By Region (Revenue, USD Billion, 2018 – 2026)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of LATAM
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of MEA
1. Research Methodology
 1.1. Research Objective
 1.2. Study Scope: Market Segments
 1.3. Study Timeframe, Limitations & Currency
 1.4. Domain-Assisted Cognition (DAC) Framework
  1.4.1. Three-stage Research Methodology
   1.4.1.1. Understand Ecosystem
    1.4.1.1.1. Secondary Research
    1.4.1.1.2. Primary Research
    1.4.1.1.3. Internal Repository
   1.4.1.2. Synthesize Information
    1.4.1.2.1. Data Analysis
    1.4.1.2.2. Data Triangulation
   1.4.1.3. Predict/Project Growth
    1.4.1.3.1. Market Size Estimation
     1.4.1.3.1.1. Bottom-up Approach
     1.4.1.3.1.2. Top-down Approach
     1.4.1.3.2. Data Validation
  1.4.2. Two-stage Quality Check Mechanism
   1.4.2.1. Inspection & Reporting
   1.4.2.2. Quality Audit
2. Market Summary
 2.1. Market Definition & Market Landscape
 2.2. Market Segment Snapshot
 2.3. Geographic Market Snapshot
3. Market Dynamics
 3.1. Market Driver Analysis
  3.1.1. Rising incidences of diabetic patients
  3.1.2. Growing vision concerns among patients with diabetes
  3.1.3. Increasing old-age population
  3.1.4. Technological advancement
 3.2. Market Restraint Analysis
  3.2.1. Adverse effects of treatment
  3.2.2. Inadequate diagnosis
 3.3. Market Opportunities
  3.3.1. Increasing awareness for advanced medication
  3.3.2. Rising medical expenditure by consumers for premium health services
4. Industry Outlook
 4.1. Key Market Trends
 4.2. Value Chain Analysis
 4.3. Porter’s 5 Forces Analysis
 4.4. Pricing Analysis (2018-2020)
 4.5. Product Benchmarking
5. Covid-19 Impact and Deviation Analysis
 5.1. Covid-19 Prevalence Analysis
 5.2. Key Market Trends
 5.3. Market Size Deviation Analysis (2020-2026)
6. Diabetic Retinopathy Market Size and Forecast, by Type (2018-2026), USD Million
 6.1. Non-Proliferative
 6.2. Proliferative
7. Diabetic Retinopathy Market Size and Forecast, by Management (2018-2026), USD Million
 7.1. Intraocular Steroid Injection
 7.2. Anti VEGF
 7.3. Vitrectomy
 7.4. Laser Surgery
8. Diabetic Retinopathy Market, Regional Analysis (2018-2026), USD Million
 8.1. North America
  8.1.1. Introduction
   8.1.1.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.1.1.2. Market Size & Forecast, by Management (2018-2026), USD Million
   8.1.1.3. Market Size & Forecast, by Country (2018-2026), USD Million
  8.1.2. U.S.
   8.1.2.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.1.2.2. Market Size & Forecast, by Management (2018-2026), USD Million
  8.1.3. Canada
   8.1.3.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.1.3.2. Market Size & Forecast, by Management (2018-2026), USD Million
 8.2. Europe
  8.2.1. Introduction
   8.2.1.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.2.1.2. Market Size & Forecast, by Management (2018-2026), USD Million
   8.2.1.3. Market Size & Forecast, by Country (2018-2026), USD Million
  8.2.2. Germany
   8.2.2.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.2.2.2. Market Size & Forecast, by Management (2018-2026), USD Million
  8.2.3. UK
   8.2.3.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.2.3.2. Market Size & Forecast, by Management (2018-2026), USD Million
  8.2.4. France
   8.2.4.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.2.4.2. Market Size & Forecast, by Management (2018-2026), USD Million
  8.2.5. Spain
   8.2.5.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.2.5.2. Market Size & Forecast, by Management (2018-2026), USD Million
  8.2.6. Italy
   8.2.6.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.2.6.2. Market Size & Forecast, by Management (2018-2026), USD Million
  8.2.7. Russia
   8.2.7.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.2.7.2. Market Size & Forecast, by Management (2018-2026), USD Million
  8.2.8. Rest of Europe
   8.2.8.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.2.8.2. Market Size & Forecast, by Management (2018-2026), USD Million
 8.3. Asia Pacific (APAC)
  8.3.1. Introduction
   8.3.1.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.3.1.2. Market Size & Forecast, by Management (2018-2026), USD Million
   8.3.1.3. Market Size & Forecast, by Country (2018-2026), USD Million
  8.3.2. China
   8.3.2.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.3.2.2. Market Size & Forecast, by Management (2018-2026), USD Million
  8.3.3. Japan
   8.3.3.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.3.3.2. Market Size & Forecast, by Management (2018-2026), USD Million
  8.3.4. India
   8.3.4.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.3.4.2. Market Size & Forecast, by Management (2018-2026), USD Million
  8.3.5. Australia
   8.3.5.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.3.5.2. Market Size & Forecast, by Management (2018-2026), USD Million
  8.3.6. South Korea
   8.3.6.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.3.6.2. Market Size & Forecast, by Management (2018-2026), USD Million
  8.3.7. Rest of Asia Pacific
   8.3.7.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.3.7.2. Market Size & Forecast, by Management (2018-2026), USD Million
 8.4. Latin America (LATAM)
  8.4.1. Introduction
   8.4.1.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.4.1.2. Market Size & Forecast, by Management (2018-2026), USD Million
   8.4.1.3. Market Size & Forecast, by Country (2018-2026), USD Million
  8.4.2. Brazil
   8.4.2.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.4.2.2. Market Size & Forecast, by Management (2018-2026), USD Million
  8.4.3. Mexico
   8.4.3.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.4.3.2. Market Size & Forecast, by Management (2018-2026), USD Million
  8.4.4. Argentina
   8.4.4.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.4.4.2. Market Size & Forecast, by Management (2018-2026), USD Million
  8.4.5. Rest of LATAM
   8.4.5.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.4.5.2. Market Size & Forecast, by Management (2018-2026), USD Million
 8.5. Middle East & Africa (MEA)
  8.5.1. Introduction
   8.5.1.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.5.1.2. Market Size & Forecast, by Management (2018-2026), USD Million
   8.5.1.3. Market Size & Forecast, by Country (2018-2026), USD Million
  8.5.2. South Africa
   8.5.2.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.5.2.2. Market Size & Forecast, by Management (2018-2026), USD Million
  8.5.3. Saudi Arabia
   8.5.3.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.5.3.2. Market Size & Forecast, by Management (2018-2026), USD Million
  8.5.4. Rest of MEA
   8.5.4.1. Market Size & Forecast, by Type (2018-2026), USD Million
   8.5.4.2. Market Size & Forecast, by Management (2018-2026), USD Million
9. Competitor Analysis
 9.1. Market Player Comparison
 9.2. Product-wise Player Mapping
 9.3. Region-wise Player Mapping
 9.4. Market Share Analysis
 9.5. Market Position Analysis
 9.6. Recent Development Analysis
10. Company Profiles
 10.1. Kowa Group (Japan)
  10.1.1. Company Overview
  10.1.2. Company Financials
  10.1.3. Product Portfolio
  10.1.4. Recent Developments
 10.2. BCN Peptides (Spain)
  10.2.1. Company Overview
  10.2.2. Company Financials
  10.2.3. Product Portfolio
  10.2.4. Recent Developments
 10.3. Ampio Pharmaceuticals, Inc. (U.S.)
  10.3.1. Company Overview
  10.3.2. Company Financials
  10.3.3. Product Portfolio
  10.3.4. Recent Developments
 10.4. Alimera Sciences, Inc. (U.S.)
  10.4.1. Company Overview
  10.4.2. Company Financials
  10.4.3. Product Portfolio
  10.4.4. Recent Developments
 10.5. Glycadia Inc. (U.S.)
  10.5.1. Company Overview
  10.5.2. Company Financials
  10.5.3. Product Portfolio
  10.5.4. Recent Developments
 10.6. F. Hoffmann-La Roche AG (Switzerland)
  10.6.1. Company Overview
  10.6.2. Company Financials
  10.6.3. Product Portfolio
  10.6.4. Recent Developments
 10.7. Oxurion (Belgium)
  10.7.1. Company Overview
  10.7.2. Company Financials
  10.7.3. Product Portfolio
  10.7.4. Recent Developments
 10.8. AbbVie Inc. (U.S.);
  10.8.1. Company Overview
  10.8.2. Company Financials
  10.8.3. Product Portfolio
  10.8.4. Recent Developments
 10.9. Regeneron Pharmaceuticals, Inc. (U.S.)
  10.9.1. Company Overview
  10.9.2. Company Financials
  10.9.3. Product Portfolio
  10.9.4. Recent Developments
 10.10. Bayer AG (Germany)
  10.10.1. Company Overview
  10.10.2. Company Financials
  10.10.3. Product Portfolio
  10.10.4. Recent Developments
 10.11. Novartis International AG (Switzerland)
  10.11.1. Company Overview
  10.11.2. Company Financials
  10.11.3. Product Portfolio
  10.11.4. Recent Developments
(Note: Financials are captured for public listed companies)

Key questions addressed by the research report-

  1. What are the current market trends and future market forecast from 2020 to 2026 for diabetic retinopathy market?
  2. What are the market dynamics and probable opportunities for market players during the forecast period?
  3. Initiatives undertaken by market players to address the COVID-19 impact to sustain in the competitive market
  4. Which geographies have immense opportunities in different segments of the diabetic retinopathy market?
  5. What are the recent strategies adopted by market players such as product launch, partnership, agreement, collaboration, merger & acquisition, and geographical expansion?


    Have any question? Check your free sample before purchase or connect with our expert.

    Additional information

    Licensing Types

    , , ,

    Enquire about Diabetic Retinopathy Market Analysis by Type (Non-Proliferative, Proliferative), by Management (Intraocular Steroid Injection, Anti VEGF, Vitrectomy, Laser Surgery), and by Region - Forecast to 2026